Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 392

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 392
---
 rely on any such in -licensedpatent rights of any third party. To date, we have not developed any patentable products. Copyrights Heritas Argentina copyright is registered in Argentina, Paraguay, Mexico, Dominican Republic, Costa Rica and Panama. The Rewell copyright is registered in Argentina, Mexico, Peru, Chile and Colombia. Services Agreements CIBIC Pursuant to the Commercialization Agreement, we appointed CIBIC, one of our indirect shareholders, as exclusive agent for the commercialization of Heritas Diagnostics tests in Argentina. CIBIC cannot commercialize outside of Argentina without Heritas Argentina’s consent. The Commercialization Agreement’s term is 30 years, which 197 shall be automatically renewed for ten additional years at its term. In addition, CIBIC is not entitled to any of our intellectual property rights, trade secrets, or know -howassociated with the NGS tests. We grant CIBIC an exclusive, royalty -freelicense to use the Heritas brand for marketing NGS tests. Pursuant to the Commercialization Agreement, we, through Heritas Argentina, sell NGS tests to CIBIC at a price determined by pre -agreedpricing lists, after which CIBIC resells these NGS tests to its clients. Further, in accordance with the Commercialization Agreement, Heritas Argentina may update the NGS tests pricing lists at its discretion following five business days’ written notice to CIBIC. Heritas Argentina invoices CIBIC for NGS tests monthly. Pursuant to the Commercialization Agreement, CIBIC is authorized to supply the requisite reagents and equipment according to the specifications and requirements of Heritas Argentina. Additionally, CIBIC is responsible for covering the maintenance expenses of the equipment used in connection with the Commercialization Agreement. In return, we, through Heritas Argentina, provide CIBIC with related analytical services and deliver the final report with test results in accordance with the Commercialization Agreement. The pricing structure for NGS tests varies based on complexity and intended use. Solely for the convenience of the reader, amounts in Argentine Pesos have been translated into U.S. dollars at the exchange rate as of December31, 2024 of Ps.1,052.50 to U.S.$1.00. Accordingly, the dollar -equivalentcost of individual tests ranges approximately from U.S.$35 to U.S.$360. These tests fall into three broad pricing bands based on complexity and scope of analysis: foundational (e.g., BRCA 1 and